Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives

Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study

(2011) K.I. Sombolos et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Perioperative thrombocytopenia in cardiac surgical patients — incidence of heparin-induced thrombocytopenia, morbidities and mortality

(2010) Matthias Thielmann et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice

(2010) Paul Zufferey et al.   THROMBOSIS AND HAEMOSTASIS

FDA approves first biological product derived from transgenic animal

(2009) G. Lavine   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation

(2009) F. Ni Ainle et al.   BLOOD

Update on heparin: what do we need to know?

(2009) Daniel S. Weitz et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Serious Anaphylactic Reactions due to Protamine Sulfate: A Systematic Literature Review

(2008) Mads Nybo et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Guideline on antiplatelet and anticoagulation management in cardiac surgery

(2008) Joel Dunning et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy

(2008) P. SAVI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Outbreak of Adverse Reactions Associated with Contaminated Heparin

(2008) David B. Blossom et al.   NEW ENGLAND JOURNAL OF MEDICINE